Protalix BioTherapeutics, Inc. (PLX) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | Gross Profit |
| Revenue | 80.62M USD | |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $80.62M | (m) | (m) |
| 2026-03-31 | (m) | $76.38M | (m) | (m) |
| 2025-12-31 | (m) | $52.74M | (m) | (m) |
| 2025-09-30 | (m) | $61.84M | (m) | (m) |
| 2025-06-30 | (m) | $61.95M | (m) | (m) |
| 2025-03-31 | (m) | $59.76M | (m) | (m) |
| 2024-12-31 | (m) | $53.40M | (m) | (m) |
| 2024-09-30 | (m) | $45.67M | (m) | (m) |
| 2024-06-30 | (m) | $38.05M | (m) | (m) |
| 2024-03-31 | (m) | $59.65M | (m) | (m) |
| 2023-12-31 | (m) | $65.49M | (m) | (m) |
| 2023-09-30 | (m) | $63.63M | (m) | (m) |
| 2023-06-30 | (m) | $67.46M | (m) | (m) |
| 2023-03-31 | (m) | $41.14M | (m) | (m) |
| 2022-12-31 | (m) | $47.64M | (m) | (m) |
| 2022-09-30 | (m) | $47.57M | (m) | (m) |
| 2022-06-30 | (m) | $45.44M | (m) | (m) |
| 2022-03-31 | (m) | $43.12M | (m) | (m) |
| 2021-12-31 | (m) | $38.35M | (m) | (m) |
| 2021-09-30 | (m) | $49.30M | (m) | (m) |
| 2021-06-30 | (m) | $48.03M | (m) | (m) |
| 2021-03-31 | (m) | $52.57M | (m) | (m) |
| 2020-12-31 | (m) | $62.90M | (m) | (m) |
| 2020-09-30 | (m) | $61.16M | (m) | (m) |
| 2020-06-30 | (m) | $64.62M | (m) | (m) |
| 2020-03-31 | (m) | $65.90M | (m) | (m) |
| 2019-12-31 | (m) | $54.69M | (m) | (m) |
| 2019-09-30 | (m) | $63.95M | (m) | (m) |
| 2019-06-30 | (m) | $50.37M | (m) | (m) |
| 2019-03-31 | (m) | $40.13M | (m) | (m) |
| 2018-12-31 | (m) | $34.24M | (m) | (m) |
| 2018-09-30 | $1.11M | $9.69M | (m) | 11.48% |
| 2018-06-30 | $3.83M | $16.55M | (m) | 23.12% |
| 2018-03-31 | $4.84M | $20.91M | (m) | 23.15% |
| 2017-12-31 | $4.01M | $19.24M | (m) | 20.85% |
| 2017-09-30 | $3.23M | $18.85M | (m) | 17.11% |
| 2017-06-30 | $2.19M | $16.00M | (m) | 13.67% |
| 2017-03-31 | $1.45M | $11.41M | (m) | 12.67% |
| 2016-12-31 | $801.00K | $9.20M | (m) | 8.71% |
| 2016-09-30 | $672.00K | $7.12M | (m) | 9.44% |
| 2016-06-30 | $1.36M | $3.78M | (m) | 36.02% |
| 2016-03-31 | $2.38M | $3.35M | (m) | 71.02% |
| 2015-12-31 | $3.63M | $4.36M | (m) | 83.27% |
| 2015-09-30 | $8.58M | (m) | (m) | (m) |
| 2015-06-30 | $6.99M | $12.70M | (m) | 55.02% |
| 2015-03-31 | $5.49M | $11.35M | (m) | 48.42% |
| 2014-12-31 | $6.11M | $13.65M | (m) | 44.74% |
| 2014-09-30 | $5.87M | $13.88M | (m) | 42.29% |
| 2014-06-30 | $5.73M | $13.77M | (m) | 41.64% |
| 2014-03-31 | $6.40M | $13.61M | (m) | 47.02% |
| 2013-12-31 | $6.08M | $10.48M | (m) | 58.07% |
| 2013-09-30 | $5.38M | $9.29M | (m) | 57.98% |
| 2013-06-30 | $6.64M | $10.73M | (m) | 61.86% |
| 2013-03-31 | $26.87M | $34.58M | (m) | 77.71% |
| 2012-12-31 | $26.28M | $34.87M | (m) | 75.37% |
| 2012-09-30 | $27.70M | $36.06M | (m) | 76.83% |
| 2012-06-30 | $25.36M | $33.47M | (m) | 75.77% |
| 2012-03-31 | $-1.37M | $8.12M | (m) | -16.89% |
| 2011-12-31 | $1.44M | $8.39M | (m) | 17.21% |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | $6.86M | $6.64M | (m) | 103.30% |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-3.19M | $388.00K | (m) | -821.39% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |